British Gynaecological Cancer Society/British Association of Gynaecological Pathology consensus for germline and tumor testing for
BRCA1 protein
BRCA2 protein
fallopian tube neoplasms
ovarian neoplasms
Journal
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
ISSN: 1525-1438
Titre abrégé: Int J Gynecol Cancer
Pays: England
ID NLM: 9111626
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
05
10
2020
revised:
06
12
2020
accepted:
09
12
2020
pubmed:
21
1
2021
medline:
24
12
2021
entrez:
20
1
2021
Statut:
ppublish
Résumé
The British Gynecological Cancer Society and the British Association of Gynecological Pathologists established a multidisciplinary consensus group comprising experts in surgical gynecological oncology, medical oncology, genetics, and laboratory science, and clinical nurse specialists to identify the optimal pathways to
Identifiants
pubmed: 33468564
pii: ijgc-2020-002112
doi: 10.1136/ijgc-2020-002112
doi:
Substances chimiques
BRCA1 Protein
0
BRCA1 protein, human
0
BRCA2 Protein
0
BRCA2 protein, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
272-278Subventions
Organisme : Chief Scientist Office
ID : SCD/11
Pays : United Kingdom
Commentaires et corrections
Type : ErratumIn
Informations de copyright
© IGCS and ESGO 2021. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: SS has received honoraria from Astra Zeneca outside the submitted work. CF has received honoraria from Ethicon, Tesaro, MSD/Astra Zeneca, Clovis, Roche, GSK. RM reports grants from Barts Charity, grants from The Eve Appeal, personal fees from Astra Zeneca, MSD, outside the submitted work. RB reports personal fees from GSK, personal fees from AstraZeneca, personal fees from Clovis, from Tesaro, outside the submitted work. RE reports personal fees from Astra Zeneca, personal fees from Clovis Pharma, personal fees from GSK, outside the submitted work.